



52375984

CONFIDENTIAL

# Genetic Result - Integrated BRACAnalysis®

## BRCA1 and BRCA2 Analysis

BRACAnalysis®



Powered by

**RECEIVING HEALTHCARE PROVIDER****Test HCP, MD**

Test Medical Center  
123 Main St  
Testville, TX 55555

**SPECIMEN**

Specimen Type: **Blood**  
Draw Date: **Jun 09, 2016**  
Accession Date: **Jun 09, 2016**  
Report Date: **Jun 14, 2016**

**PATIENT**

Name: **Pt Last Name,  
Pt First Name**  
Date of Birth:  
Patient ID: **Patient id**  
Gender: **Female**  
Accession #: **07001267-BLD**  
Requisition #: **7001267**

**RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED**

Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with the potential to alter medical intervention.

**ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED**

**Details About Non-Clinically Significant Variants:** All individuals carry DNA changes (i.e., variants), and most variants do not increase an individual's risk of cancer or other diseases. When identified, variants of uncertain significance (VUS) are reported. Likely benign variants (Favor Polymorphisms) and benign variants (Polymorphisms) are not reported and available data indicate that these variants most likely do not cause increased cancer risk. Present evidence does not suggest that non-clinically significant variant findings be used to modify patient medical management beyond what is indicated by the personal and family history and any other clinically significant findings.

**Variant Classification:** Myriad's myVision™ Variant Classification Program performs ongoing evaluations of variant classifications. In certain cases, healthcare providers may be contacted for more clinical information or to arrange family testing to aid in variant classification. When new evidence about a variant is identified and determined to result in clinical significance and management change, that information will automatically be made available to the healthcare provider through an amended report.

**ADDITIONAL INFORMATION****GENES ANALYZED**

Unless otherwise noted sequencing and large rearrangement analyses were performed on the following genes:

*BRCA1, BRCA2*

**Indication for Testing:** It is our understanding that this individual was identified for testing due to a personal or family history suggestive of a hereditary predisposition for cancer.

**Associated Cancer Risks and Clinical Management:** If a clinically significant mutation is identified, please see the management tool associated with this report for a summary of cancer risk and professional society medical management guidelines that may be useful in developing a plan for this patient. Testing of other family members may assist in the interpretation of this patient's test result.

**Analysis Description:** The Technical Specifications summary (<https://www.myriadpro.com/documents-and-forms/technical-specifications/>) describes the analysis, method, performance, nomenclature, and interpretive criteria of this test. Current testing technologies are unable to definitively determine whether a variant is germline or somatic in origin, which may significantly impact risk estimates and medical management; therefore, these results should be correlated with this patient's personal and family history. The interpretation of this test may also be impacted if the patient has a hematologic malignancy or an allogeneic bone marrow transplant.

THE CLASSIFICATION AND INTERPRETATION OF ALL VARIANTS IDENTIFIED IN THIS ASSAY REFLECTS THE CURRENT STATE OF MYRIAD'S SCIENTIFIC UNDERSTANDING AT THE TIME THIS REPORT WAS ISSUED. VARIANT CLASSIFICATION AND INTERPRETATION MAY CHANGE FOR A VARIETY OF REASONS, INCLUDING BUT NOT LIMITED TO, IMPROVEMENTS TO CLASSIFICATION TECHNIQUES, AVAILABILITY OF ADDITIONAL SCIENTIFIC INFORMATION, AND OBSERVATION OF A VARIANT IN MORE PATIENTS.



© 2016 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615  
The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes of diagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, the Myriad logo, Myriad myRisk, BRACAnalysis, COLARIS, myVision and the myVision logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.

**Genetic Result - Integrated BRACAnalysis®**Name: **Pt Last Name, Pt First Name**

DOB:

Accession #: **07001267-BLD**Report Date: **Jun 14, 2016**

---

**Please contact Myriad Medical Services at 1-800-469-7423 X 3850 to discuss any questions regarding this result.**

This **Authorized Signature**  
pertains to this laboratory report:

**Benjamin B. Roa, PhD**  
Diplomate ABMG  
Laboratory Director

**Johnathan M. Lancaster, MD, PhD**  
Diplomate FACOG, FACS  
Chief Medical Officer

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. The patient's clinical history and test results should not be disclosed to a third party, unless related to treatment or payment for treatment, without the patient's express written authorization. It is strongly recommended that these results be communicated to the patient in a setting that includes appropriate counseling. This test was developed and its performance characteristics determined by Myriad Genetic Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that clearance or approval for laboratory-developed tests is not required.

